You are here: Industry Insights > Biopharma

News List

Biopharma increasingly factoring sustainability into cold chain decisions europeanpharmaceuticalreview
July 31, 2020
A survey has found that the biopharma industry is taking sustainability into their cold chain considerations more and more, with 66 percent saying it is very important.
WuXi Biologics to Open Clinical Mfg. Facility in Cranbury, NJ contractpharma
June 10, 2020
Will install total 6000 L bioreactors, Process Development (PD), Quality Control (QC) labs, along with supporting functions.
Financial Report -Pfizer contractpharma
April 30, 2020
Biopharma revenues up 11% in the quarter to $10.0 billion; generic competition impacts Upjohn revenues.
Cambrex Completes Biopharma Expansion contractpharma
April 08, 2020
The Durham, NC site now features a range of new instruments, including particle analysis and imaging.
Biopharma industry leaders collaborate to combat COVID-19 europeanpharmaceuticalreview
March 30, 2020
The International Federation of Pharmaceutical Manufacturers and Associations has announced that the biopharma industry has responding swiftly to the COVID-19 pandemic and will further increase its efforts.
Thermo Fisher Scientific Continues Biopharma Investments contractpharma
March 24, 2020
Further invests $475 million in biopharma capabilities to help accelerate commercialization.
The top 10 largest biopharma M&A deals in 2019 fiercepharma
January 07, 2020
Biopharma M&A got a big boost moneywise in 2019. The three largest—Bristol-Myers Squibb for Celgene, AbbVie for Allergan, and Amgen for Celgene’s psoriasis drug Otezla—together delivered more than $150 billion. Valued at $74 billion ...
Evolving World of Pharma: Demand for biologics is predicted to grow at 10% per year over the next 4-5 years Sarah Harding
November 24, 2019
As biopharmaceuticals continue to grow at a rapid place, a number of trends are impacting industry.
U.S. biopharma CEOs look outside for growth, poll finds fiercepharma
September 26, 2019
Eli Lilly went after Loxo Oncology to beef up its presence in cancer treatment, just as Amgen is paying $13.4 billion for Celgene’s Otezla to secure a larger share of the psoriasis market alongside old TNF drug Enbrel.
WCG KMR group invites Biopharma companies to enroll in Clinical Trial Cost Study biospectrumasia
September 20, 2019
All of WCG KMR Group's studies are built upon a comprehensive yet granular framework that allows for the maximum level of detail in performance reporting.

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page